305
Participants
Start Date
January 31, 2016
Primary Completion Date
July 25, 2017
Study Completion Date
July 25, 2017
Assay-guided treatment (AGT)
The assay provides information to guide pharmacotherapeutic decisions personalized to a patient's genetic profile, to maximize improvement in symptomatology and minimize treatment failure and treatment intolerability.
Treatment-as-usual (TAU)
Subjects are treated-as-usual without the aid of the assay.
Thomas Jefferson University Mood Disorder Program, Philadelphia
University of Virginia Center for Psychiatric Research, Charlottesville
Richard H Weisler MD, PA and Associates, Raleigh
Clinical Neuroscience Solutions Inc. - Jacksonville, Jacksonville
Florida Clinical Research Center, LLC - Maitland, Maitland
Clinical Neuroscience Solutions Inc. - Orlando, Orlando
Florida Clinical Research Center, LLC - Bradenton, Bradenton
University of Alabama - Birmingham, Birmingham
Clinical Neuroscience Solutions Inc. - Memphis, Memphis
Midwest Clinical Research Center, Dayton
Chicago Research Center, Inc., Chicago
Premier Psychiatric Research Institute, LLC, Lincoln
Woodland Research Northwest, Springdale
IPS Research Company, Oklahoma City
BioBehavioral Research of Austin, PC, Austin
Noesis Pharma, Phoenix
Pacific Institute of Medical Research, Los Angeles
Collaborative Neuroscience Network, Inc. - Torrance, Torrance
Pacific Clinical Research Medical Group, Upland
Artemis Institute for Clinical Research, San Diego
Collaborative Neuroscience Network, Inc. - Garden Grove, Garden Grove
Pacific Research Partners, LLC, Oakland
Boston Clinical Trials, Boston
Lead Sponsor
Collaborators (1)
Medpace, Inc.
INDUSTRY
Genomind, LLC
INDUSTRY